Phenibut 250 mg 20 tablets

Phenibut is used for asthenic and anxiety-neurotic conditions, restlessness, anxiety, fear; in children for stuttering and tics, in the elderly for insomnia; for the prevention of anxiety states occurring before surgical interventions and painful diagnostic procedures.
Phenibut is used as part of a comprehensive therapy for alcoholism to alleviate psychopathological and somatovegetative disorders in withdrawal syndrome. In combination with detoxification agents, the drug may be used to treat pre-delirious states in alcoholism.
Additionally, phenibut is prescribed for vestibular dysfunctions, including Meniere's disease; for the prevention of motion sickness in kinetoses.

Phenibut is taken orally after meals in courses of 2-3 weeks. For adults, the recommended dosage is 250-500 mg three times a day. If necessary, the daily dose may be increased to 2500 mg. For children aged 2 to 8 years, phenibut is prescribed at 50-100 mg; for those aged 8 to 14 years - 250 mg three times a day. The maximum single dose for adults is 750 mg, for individuals over 60 years - 500 mg, for children under 8 years - 150 mg, and for those aged 8 to 14 years - 250 mg.

To alleviate alcohol withdrawal syndrome, phenibut is prescribed in the first days of treatment at 250-500 mg three times a day during the day and 750 mg at night, with a gradual reduction of the daily dose to the usual for adults.

For the treatment of dizziness due to vestibular dysfunction and Meniere's disease, phenibut is prescribed at 250 mg three times a day for 14 days.

For the prevention of motion sickness, phenibut is taken at a dose of 250-500 mg once, 1 hour before the expected onset of motion or at the first signs of mild seasickness. The anti-motion sickness effect of phenibut is enhanced with an increased dosage. In cases of pronounced manifestations of seasickness (vomiting, etc.), the oral administration of phenibut is not very effective even at doses of 750-1000 mg.

Composition per tablet.
Active ingredient:
aminophenylbutyric acid hydrochloride (phenibut) - 250 mg
Excipients:
lactose monohydrate - 180 mg,
potato starch - 56 mg,
povidone (low molecular weight medical polyvinylpyrrolidone) - 9 mg
calcium stearate monohydrate - 5 mg.

Tablets of white or white with a slight yellowish tint, in a flat-cylindrical shape.

Individual intolerance, pregnancy (1st trimester), breastfeeding, age under 2 years.
Use with caution in cases of erosive-ulcerative lesions of the gastrointestinal tract, liver failure.

With prolonged use, it is necessary to monitor liver function parameters and the peripheral blood picture. It is essential to refrain from potentially hazardous activities that require increased attention.

Drowsiness, nausea. Increased irritability, agitation, anxiety, dizziness, headache (during initial doses), allergic reactions (skin rash, itching).

Increased symptoms of side effects; pronounced drowsiness, nausea, vomiting, fatty liver dystrophy (with intake over 7 g), eosinophilia, decreased blood pressure, impaired kidney function.

First aid - gastric lavage, administration of activated charcoal, and symptomatic therapy.

For mutual potentiation, phenibut can be combined with other psychotropic agents, reducing the doses of phenibut and the combined medications. It prolongs and enhances the effects of hypnotics, narcotics, neuroleptics, anticonvulsants, and alcohol. There is evidence of enhanced effects of antiparkinsonian agents under the influence of phenibut.

Phenibut is a phenyl derivative of GABA and phenylethylamine. It has anxiolytic effects, reducing tension, anxiety, fear, and improving sleep; it prolongs and enhances the effects of hypnotics, narcotics, and neuroleptics.
Phenibut is a nootropic agent that facilitates GABA-mediated transmission of nerve impulses in the central nervous system (direct action on GABAergic receptors), and also exhibits tranquilizing, psychostimulating, antiaggregant, and antioxidant effects.
It improves the functional state of the brain by normalizing tissue metabolism and influencing cerebral blood circulation (increasing the volumetric and linear velocity of cerebral blood flow, reducing resistance in cerebral vessels, improving microcirculation, and exhibiting antiaggregant effects). It contributes to the reduction or disappearance of feelings of anxiety, tension, restlessness, and fear, normalizes sleep, and has anticonvulsant effects.
It does not affect cholinergic and adrenergic receptors. It prolongs the latent period and shortens the duration and severity of nystagmus. It reduces manifestations of asthenia and vasovegetative symptoms (including headache, heaviness in the head, sleep disturbances, irritability, emotional lability), and enhances mental performance. It improves psychological indicators (attention, memory, speed, and accuracy of sensorimotor reactions). With course administration, it increases physical and mental performance, improves memory, normalizes sleep; it enhances the condition of patients with motor and speech disorders.
In patients with asthenia, it improves well-being from the first days of therapy, increasing interest and initiative (motivation for activity) without sedation or excitation.
When prescribed after severe traumatic brain injuries, it improves the course of bioenergetic processes in the brain.
In elderly individuals, it does not cause central nervous system depression, and muscle relaxant aftereffects are most often absent.
It improves microcirculation in the eye tissues and reduces the depressive effects of ethanol on the central nervous system.
The drug is low in toxicity, does not cause allergic reactions, nor does it have teratogenic, embryotoxic, or carcinogenic effects.

The absorption of the drug is high, penetrating well into all tissues of the body and across the blood-brain barrier (BBB) (approximately 0.1% of the administered dose reaches brain tissue, with significantly higher levels in young and elderly individuals). It is evenly distributed in the liver and kidneys. It is metabolized in the liver - 80 - 95%, with pharmacologically inactive metabolites. It does not accumulate. After 3 hours, it begins to be excreted by the kidneys, while the concentration in brain tissue does not decrease, and it can still be detected in the brain for another 6 hours. About 5% is excreted by the kidneys in unchanged form, partially with bile.